"Real-world Assessment of BP Control in Patients With Hypertension by the Netrod RDN System" - REACH-RDN

This study is an observational one, collecting real-world data generated in routine clinical treatment. The Netrod-RDN renal artery radiofrequency ablation system (including the renal artery radiofrequency ablation device and the disposable mesh renal artery radiofrequency ablation catheter) produced and provided by Shanghai Meiliweiye Medical Technology Co., Ltd. was used to perform percutaneous renal denervation (RDN) on patients with refractory hypertension and drug intolerance in the real world. Refractory hypertension is defined as patients whose blood pressure remains uncontrolled despite taking three or more antihypertensive drugs (including one diuretic) for more than three months; drug intolerance refers to patients who have contraindications to drugs or cannot tolerate drug administration due to adverse drug reactions.

NCT Number	NCT07273877
Lead Sponsor	Shanghai Golden Leaf MedTec Co. Ltd
Conditions	Hypertension
Enrollment	1,000 participants
Start Date	2025-08-07
Primary Completion	2026-12-30 (estimated)
Study Completion	2030-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-20